^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    AiRuiKa (camrelizumab)

    i
    Other names: INCSHR-1210, SHR1210, HR301210, HR 301210, INCSHR 1210, SHR 1210, INCSHR1210, SHR-1210, HR-301210
    Company:
    CG Invites, HLB Bio Group, Jiangsu Hengrui Pharma, NPO Petrovax
    Drug class:
    PD1 inhibitor
    Related drugs:
    2d
    Complete remission of recurrent human papillomavirus-associated cervical cancer managed with camrelizumab and nanoparticle albumin-bound paclitaxel as second-line treatment: a case report. (PubMed, Front Immunol)
    The current therapeutic protocols outlined in the National Comprehensive Cancer Network Guidelines 4.2025 edition propose that for second-line or subsequent therapies of cervical carcinoma, prioritized protocols incorporate pembrolizumab administration specifically for patients demonstrating high tumor mutational burden characteristics, positive for programmed cell death ligand 1 expression, or exhibiting microsatellite instability-high/mismatch repair deficiency molecular profiles. Other proposed therapeutic approaches include bevacizumab, paclitaxel, and nanoparticle albumin-bound paclitaxel (nab-paclitaxel)...The patient continues to undergo active clinical surveillance. Our case report illustrates that second-line immunochemotherapy utilizing camrelizumab in combination with nab-paclitaxel exhibits notable efficacy and manageable safety profile.
    Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
    |
    TMB-H • MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • AiRuiKa (camrelizumab) • albumin-bound paclitaxel
    3d
    A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial (clinicaltrials.gov)
    P2/3, N=0, Withdrawn, Women's Hospital School Of Medicine Zhejiang University | N=440 --> 0 | Active, not recruiting --> Withdrawn
    Enrollment change • Trial withdrawal • IO biomarker
    |
    cisplatin • carboplatin • paclitaxel • AiRuiKa (camrelizumab)
    8d
    A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma (clinicaltrials.gov)
    P3, N=423, Active, not recruiting, Jiangsu HengRui Medicine Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    AiRuiKa (camrelizumab) • AiTan (rivoceranib)
    9d
    Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial (clinicaltrials.gov)
    P2, N=440, Not yet recruiting, Women's Hospital School Of Medicine Zhejiang University | Initiation date: Sep 2025 --> Jan 2026
    Trial initiation date
    |
    AiRuiKa (camrelizumab)
    14d
    Nab-P+Cb+PD1 Inhibitors as Neoadjuvant Therapy for Early TNBC (clinicaltrials.gov)
    P2, N=64, Recruiting, Henan Cancer Hospital | Trial completion date: Nov 2025 --> May 2026 | Trial primary completion date: Nov 2025 --> May 2026
    Trial completion date • Trial primary completion date
    |
    carboplatin • AiRuiKa (camrelizumab)
    14d
    Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma. (PubMed, Cell Rep Med)
    Exploratory analysis indicates that responders show significantly higher tumor PD-L1 expression than non-responders do, with median tumor proportion scores of 8% and 2%, respectively. The study is registered at ClinicalTrials.gov (NCT05236699).
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • FGFR2 (Fibroblast growth factor receptor 2)
    |
    PD-L1 expression
    |
    gemcitabine • AiRuiKa (camrelizumab) • Sulanda (surufatinib)
    15d
    Neoadjuvant Immune Checkpoint Inhibition in MSI-H/dMMR Colorectal Cancer: A Systematic Review of Prospective Trials Evaluating Efficacy, Pathologic Response, and Surgical Outcomes. (PubMed, J Gastrointest Cancer)
    Neoadjuvant immune checkpoint inhibition demonstrates high pathological and clinical response rates in dMMR/MSI-H colorectal cancer, with organ preservation achievable in selected rectal cancer patients. Neoadjuvant immunotherapy may become an alternative to surgery as the primary treatment for MSI-H/dMMR colorectal cancer if long-term quality of life is superior and toxicity and cost are competitive with standard surgical approaches. However, longer follow-up, predictive biomarkers, and randomized comparisons with upfront surgery are required before its routine clinical use.
    Review • Journal • Checkpoint inhibition • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker • MSI-H • dMMR
    |
    MSI (Microsatellite instability)
    |
    MSI-H/dMMR
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • Jemperli (dostarlimab-gxly)
    16d
    Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC (clinicaltrials.gov)
    P3, N=262, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | N=192 --> 262 | Trial completion date: Jul 2027 --> Jul 2029 | Trial primary completion date: Jul 2026 --> Jul 2028
    Enrollment change • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • oxaliplatin • leucovorin calcium
    18d
    Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer (clinicaltrials.gov)
    P2, N=39, Recruiting, Women's Hospital School Of Medicine Zhejiang University | Not yet recruiting --> Recruiting | Trial completion date: Dec 2029 --> Dec 2031 | Trial primary completion date: Sep 2029 --> Dec 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    carboplatin • paclitaxel • AiRuiKa (camrelizumab)
    23d
    A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma. (clinicaltrials.gov)
    P2/3, N=737, Not yet recruiting, CSPC Megalith Biopharmaceutical Co.,Ltd.
    New P2/3 trial • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    EGFR expression
    |
    cisplatin • paclitaxel • 5-fluorouracil • AiRuiKa (camrelizumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • Enshuxing (enlonstobart) • SYS6010
    23d
    Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial (clinicaltrials.gov)
    P2, N=0, Withdrawn, Women's Hospital School Of Medicine Zhejiang University | N=59 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    AiRuiKa (camrelizumab)
    28d
    PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT (clinicaltrials.gov)
    P=N/A, N=43, Recruiting, The First Affiliated Hospital of Soochow University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Jul 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    AiRuiKa (camrelizumab) • azacitidine